psoriasis

Research in Review

Ustekinumab Superior to Tumor Necrosis Factor-Alpha Inhibitors for the Treatment of Psoriasis

02/12/2016

JCP Editors

A study of the biologic drug ustekinumab has found it to be a better treatment for psoriasis than tumor necrosis factor-alpha (TNF-α) inhibitors. The PSOLAR (Psoriasis Longitudinal Assessment and Registry) study is...

A...

02/12/2016

Journal of Clinical Pathways

Perspectives

Formulary Decisions and the Evolution of Psoriasis Treatment

12/14/2015

William Malatestinic, PharmD, MBA

David Amato, MD

Steven R. Feldman, MD, PhD

Abstract: Psoriasis is a common and significant illness characterized by systemic inflammation. In its mildest form, psoriasis can often be managed with relatively low-cost topical therapies; but for...

...

12/14/2015

Journal of Clinical Pathways